ORKA · Oruka Therapeutics, Inc.
$80.15
-1.23% last session
End-of-day data · close of 2026-10-23
Market cap
$5B
Enterprise value
$4B
Trailing P/E
—
Forward P/E
-28.0
Dividend yield
0.0%
Beta
-0.11
Avg volume
1M
Employees
0K
Daily Change %
-1.23%
5 Days Change
7.61%
10 Days Change
4.53%
30 Days Change
-6.25%
60 Days Change
-21.28%
Month to Day Change
-3.92%
Year to Day Change
164.43%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ORKA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-19
Latest call per bank · past 12 months
UBS
Buy$130
+62.2% vs priceBarclays
Overweight$160
+99.6% vs priceJefferies
Buy$45.00
-43.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | BTIG | Reiterates | Buy | $151 |
| 2026-09-24 | Wedbush | Reiterates | Outperform | $165 |
| 2026-09-24 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 2026-09-03 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 2026-08-11 | Guggenheim | Reiterates | Buy | $200 |
| 2026-08-11 | Wedbush | Reiterates | Outperform | $165 |
| 2026-08-11 | BTIG | Reiterates | Buy | $151 |
| 2026-08-03 | HC Wainwright & Co. | Reiterates | Buy | $120 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 46 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 10.9% below the 50-day MA ($89.99).
- bullish: Price vs 200-day MA: Trading 18.6% above the 200-day MA ($67.60).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.76) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($26.19) and high ($113.08).
ORKA Price Chart
Loading chart for ORKA…
Fundamentals
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.